Etanercept promotes bone formation via suppression of dickkopf-1 expression in rats with collagen-induced arthritis by Tanida, Atsushi et al.
13
Yonago Acta medica 2013;56:13–19 Original Article 
Etanercept Promotes Bone Formation via Suppression of Dickkopf-1 Expression in 
Rats with Collagen-Induced Arthritis 
Atsushi Tanida,* Yuji Kishimoto,* Toru Okano* and Hiroshi Hagino† 
*Division of Orthopedic Surgery, Department of Medicine of Sensory and Motor Organs, School of Medicine, Tottori University Faculty 
of Medicine, Yonago 683-8504, Japan and †Department of Fundamental Nursing, School of Health Science, Tottori University Faculty 
of Medicine, Yonago 683-8503, Japan
tive, independent of the regulation of osteoclast activity. 
Marked bone formation is attributed to the fact that ETN 
directly promotes osteoblastogenesis, not as a result of 
suppressing osteoclastogenesis. 
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Rheumatoid arthritis (RA) is a chronic inflammatory 
disease, accompanied by synovitis, that causes joint de-
struction. Various cytokines, including tumor necrosis 
factor (TNF)-alpha, have been implicated as important 
mediators of inflammation and joint destruction in 
RA.1–3 The scientific consensus is that the receptor ac-
tivator of nuclear factor kappa-B ligand (RANKL) and 
osteoprotegelin (OPG) system is pivotal to the pathogen-
esis of bone erosions in RA.4 Also, TNF-alpha promotes 
the expression of RANKL, and that is associated with 
up-regulation of osteoclast activity.5 
 From the point of view of bone metabolism, it has 
also become clear that TNF-alpha regulates the activ-
ity of osteoblasts, which play a role in bone metabolism 
with osteoclasts.6–8 Recently, it was reported that Dick-
kopf-1 (DKK-1), an inhibitor of the Wnt signaling path-
way, regulated the balance between osteoclastogenesis 
and osteoblastogenesis in an inflammatory joint RA 
model. TNF-alpha may suppress osteoblast differentia-
tion via promoting the expression of DKK-1, inhibiting 
Wnt the signaling pathway.9–11 
 In recent years, the development of TNF-alpha-
targeted biologic agents has provided an excellent cu-
rative effect.12–15 As previously reported, a number of 
clinical reports have described radiographic evidence of 
the repair of erosion in RA.16–19 The administration of 
etanercept (ETN), an anti TNF-alpha agent, reduced the 
total Sharp score from the baseline established before 
the initiation of therapy in a large clinical study.15 ETN 
may promote bone formation, as well as inhibiting bone 
destruction via suppression of TNF-alpha function. Al-
though there are some indications that destructive bone 
lesions can be repaired in RA joints, the mechanism of 
this repair remains unknown and histologically unprov-
en. To examine the effects of ETN on bone formation, 
ABSTRACT
Background    Various clinical reports suggest etan-
ercept (ETN) has some efficacy in bone formation in 
rheumatoid arthritis (RA). To examine this effect, we 
investigated the gene expression of cytokines relevant to 
osteoblast/osteoclast differentiation, and evaluated his-
tomorphometric findings in mature rats with collagen-
induced arthritis (CIA). 
Methods    Total RNA was extracted from knee joints 
with CIA after ETN or placebo administration. Subse-
quently, realtime-PCR was carried out to quantify the 
mRNAs encoding Wnt-1, Dickkopf-1 (DKK-1), receptor 
activator of nuclear factor kappa-B ligand (RANKL), 
osteoprotegelin (OPG) and TNF (tumor necrosis factor)-
alpha. In histomorphometric analysis, the infiltrating 
pannus volume and pannus surface, and the following 
items in contact with pannus surface were measured: os-
teoclast number, osteoid surface, osteoid volume and la-
beling surface. These were evaluated in the distal femur 
with CIA with or without ETN administration. 
Results    TNF-alpha, RANKL and OPG mRNA 
expressions, linked to osteoclastogenesis, were not 
significantly different with or without ETN administra-
tion. ETN administration significantly increased Wnt-1 
mRNA expression, the osteoblast promoter, and de-
creased DKK-1 mRNA expression, the Wnt signal in-
hibitor. In histomorphometric analysis, pannus volume, 
pannus surface and osteoclast number, parameters of 
bone destruction, were not significantly different among 
groups. Osteoid volume, osteoid surface and labeling 
surface, parameters of bone formation, increased signifi-
cantly with ETN administration. 
Conclusion    Our results suggest that ETN suppresses 
DDK-1 expression, and, as a result, Wnt expression is 
promoted and osteoblastogenesis becomes more ac-
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we i) investigated the gene expression of cytokines rel-
evant to osteoblast differentiation within bone infiltrated 
by pannus (Experiment A), and ii) performed histologi-
cal evaluation of bone repair (Experiment B) in mature 
rats with collagen-induced arthritis (CIA), an animal 





Seven-month-old female Sprague-Dawley rats (retired 
breeding animals, body weight 266–381 g, Shimizu 
Laboratory Supply, Kyoto, Japan) were used in this 
experiment. This experiment was carried out in accor-
dance with the Guidelines for Animal Experimentation 
of the Faculty of Medicine, Tottori University. During 
this experiment, animals were freely fed with tap water 
and food (CE-2; CLEA, Tokyo, Japan; calcium content 
1.18 g/100 g, phosphorus content 1.09 g/100 g, vitamin 
D3 content 250 IU/100 g). The room temperature was 
set to 24 ˚C, and after about 2 weeks of preliminary 
breeding, the animals were used for the experiments. 
Collagen arthritis models
According to the method described by Trentham et al.,20 
1 mL of emulsion containing 0.5 mg bovine type II col-
lagen (0.3% acetic acid solution; K-41 Cosmo-Bio, To-
kyo) and 0.5 mg of incomplete Freund’s adjuvant (521-
00021; Difco Laboratories, Detroit, MI) were injected 
intracutaneously at three sites on the back of CIA group 
rats, and 1 week later, a half dosage of the same emul-
sions was injected. In the non-immunized group (N 
group), physiological saline was injected in the same 
manner. The development of arthritis was judged by the 
redness and swelling in the ankle by same observer. The 
onset of arthritis was observed about 2 weeks after im-
munization, and arthritis became severe until 4 weeks.
Administration of biologic agents 
In the ETN administration group, rats were subcutane-
ously administered 3 mg/kg ETN 3 times per week (E 
group). In the placebo-administered group, physiological 
saline was injected in the same manner (P group).
 
Experiment A: Analysis of mRNA expression
Animal grouping and ETN administration
The animals were divided randomly into 3 groups: E 
group (n = 21), P group (n = 21) and non-immunized 
group (N group) (n = 5). Administrations of ETN (E 
group) and placebo (P group) were started 1 day after 
immunization, and 7 animals were killed 7, 14 and 21 
days after immunization in each group. 
Tissue collection and RNA isolation
After the animals were killed, the bilateral distal femur 
and proximal tibia (cut off 5 mm from the joint line) were 
collected and cooled with liquid nitrogen immediately. 
The bone tissues were collected aseptically and all con-
nective tissue, including the periosteum, was completely 
removed. Frozen bones were homogenized in appropriate 
volumes in an Isogen Kit (Nippon Gene, Tokyo) using 
POLYTRON (KINEMATICA AG, Tokyo). Total RNA 
was extracted from the tissue homogenates according to 
the manufacturer’s instructions. Additionally, we defecat-
ed the extracted total RNA using an RNeasy plus mini 
kit (Quiagen, Hilden, Germany). RNA concentrations 
were determined by spectrophotometry.
 
Reverse transcription
The total RNA was reverse-transcribed into cDNA using 
M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, 
CA). The conditions were as follows: incubation 60 min 
at 37 ˚C, reaction inactivation by heating at 95 ˚C for 5 
min, and maintenance at 4 ˚C. 
 
Real-time PCR
Rat primers were used to analyze DKK-1, Wnt-1, 
RANKL, OPG, TNF-alpha and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH, housekeeping gene), 
respectively. Specific primers designed with reference 
to the Universal ProbeLibrary Assay Design Center and 
Universal ProbeLibrary Probe (Roche Applied Science, 
Madison, WI) were used as shown in Table 1. A quanti-
tative real-time PCR was performed to compare expres-
sion levels of each mRNA. EXPRESS qPCR Supermix 
with Premixed ROX (Invitrogen) was used, with an 
initial denaturation step of 20 s at 95 ˚C, followed by 45 
cycles of 1 s at 95 ˚C, and 20 s at 60 ˚C as the annealing 
temperature. Relative quantification of mRNA expres-
sion was calculated by a 7900HT Fast Real-Time PCR 
System with SDS2.3 software (Applied Biosystems, 
Carsbad, CA).
 
Experiment B: Histological findings
Animal grouping and ETN administration
Twenty rats were immunized and divided into the E 
group (n = 10) and P group (n = 10), and killed 8 weeks 
after CIA immunization. ETN administration was start-
ed 3 weeks after immunization because bone destruction 
was observed histologically 3 weeks after immuniza-
tion.21
 
Preparation of hard tissue specimens
Histological findings in hard tissue specimens were 
taken from the medial condyle of the femur in the mid-
sagittal plane then compared between the groups. Bone 
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labeling by subctaneous injection of calcein at 10 mg/kg 
was performed twice at 17 days and 1 day before the an-
imals were killed, and tetracycline at 20 mg/kg was giv-
en once at 9 days before the animals were killed [schedule 
1/7/1/7/1 (number of days of the 1st labeling/number of 
days between 1st and 2nd labeling/number of days of the 
2nd labeling/number of days between 2nd labeling and 
3rd labeling/number of days between 3rd labeling and 
killing)]. The labeling schedule was decided as the result 
of trial and error of preliminary experiment. The knee 
joint with larger swelling in each rat was collected with 
the joint capsule and synovial membranes preserved, 
and fixed in 70% alcohol. The remaining whole knee 
joint was stained with Villaneuva bone stain for 7 days, 
dehydrated in graded concentrations of ethanol, and em-
bedded in methyl-methacrylate without decalcification. 
The resulting blocks of knee joint specimens were sec-
tioned in the sagittal plane at a thickness of 5 μm with a 
microtome (Leica Biosystems, Solms, Germany). 
 
Bone histomorphometry 
Bone histomorphometric measurements of the femur 
were made using a semiautomatic image analyzing sys-
tem (System Supply, Nagano, Japan) and a fluorescent 
microscope (eclipse 80i; Nikon, Tokyo) set at a magni-
fication power of 400. Because it was difficult to quan-
tify bone formation after definite destructive action, we 
regarded osteoid production and bone calcification seen 
on the surface of the pannus as evidence of the repair of 
erosion. Twenty sections closest to the mid-sagittal plane 
of the medial femoral condyle were sampled for each 
group, 2 sections per rat, each parameter was measured 
and the average was compared among the different 
groups. A line connecting the intersection of the epiphy-
Table 1. Primers used for real-time PCR
 Left primer  Used probe  Product  Accession 
Molecule Right  primer number (base pairs) number
TNF-alpha 5’-agttggggagggagacctt-3’ 71 60 L00981
 5’-catccacccaaggatgtttag-3’
RANKL 5’-agacacagaagcactacctgactc-3’ 2 90 AF187319
 5’-ggccccacaatgtgttgta-3’
OPG 5’-gaagcaactcaaaattgtggaa-3’ 98 94 U94330
 5’-tcagccaattcggtataatcttg-3’
TRAP 5’-gcctcttgcgtcctctatga-3’ 65 60 M76110
 5’-agcaccatccacgtatcca-3’
DKK-1 5’-cgggaattactgcaaaaacg-3’ 76 83 NM001106350
 5’-caatgatgccttcctcgatt-3’
Wnt-1 5’-tcggcaagatcgtcaacc-3’ 15 128 NM001105714
 5’-gtagtcgcaggtgcaggatt-3’
GAPDH 5’-acaactttggcatcgtgga-3’ 114 62 NM017008
 5’-cttctgagtggcagtgatgg-3’
DKK-1, Dickkopf-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; OPG, osteoprotegelin; RANKL, receptor activator of nuclear 
factor kappa-B ligand; TNF, tumor necrosis factor; TRAP, tartrate-resistant acid phosphatase. 
Fig. 1. Schematic presentations of unit 
area (a) and infiltrating pannus (b).
 a: Epiphyseal bone marrow is divided 
into 3 regions (A1-A3) by 2 lines 
connecting 2 points, each equally 
dividing lines E1-E2 and C1-C2 
into 3 portions.
b: We defined the shaded area as the 
pannus infiltrating the epiphyseal 
medulla of the posteromedial femo-
ral condyle. 
  C,  cartilage; 
 C-CL,  the line connecting the 
remaining edge of the 
posterior cortex to the 
posterior cartilage; 
 EL,  epiphyseal line; 
 FC,  femoral condyle; 
 PC,  posterior cortex.
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seal line and the anterior cortex (E1) to the intersection 
of the epiphyseal line and the posterior cortex (E2) was 
equally divided into 3 portions, and the 2 division points 
were connected to 2 points equally dividing into 3 the 
line connecting the anterior end (C1) with the posterior 
end (C2) of the articular cartilage; the bone marrow was 
thus divided into 3 regions: A1 to A3. We defined the 
A3 region as a unit area (tissue volume) (Fig. 1A).21 To 
measure the pannus volume and pannus surface infiltrat-
ing the epiphyseal medulla of the posteromedial femoral 
condyle, we chose the line connecting the remaining 
edge of the posterior cortex to the posterior cartilage 
(C-CL) (Fig. 1B). We defined the shaded area as the in-
filtrating pannus. The pannus surface was measured in 
this area exclusive of the surface on the C-CL. Then, the 
following items in contact with the pannus surface were 
measured: osteoclast number, osteoid surface, osteoid 
volume and labeling surface. We also counted the num-
ber of plasma cells, macrophages, and synovial blood 
vessels per high power field (HPF) in the same area to 
assess the activity of the infiltrating pannus. The field 
was inclusive of the pannus close to the bone surface, 
but exclusive of bone tissue.
Statistical analysis
Statistical significance was analysed using the soft-
ware package Dr. SPSS 2 for Windows 11.0.1J (SPSS, 
Tokyo). In experiment A, Fisher’s protected least sig-
nificant difference procedure was performed after re-
peated-measures analysis of variance. In experiment B, 
the Mann-Whitney U test was used to compare median 





Experiment A: Analysis of mRNA expression
Expression of TNF-alpha increased significantly with 
time in the E group (P = 0.005), and tended to increase 
over the course of time in the P group (P = 0.065) (Fig. 2). 
Compared with the N group, significant differences 
were shown on day 21 in both the E and P groups (P = 
0.033, 0.035, respectively). Expression of RANKL in the 
P group tended to increase over time, whereas in the E 
group it showed no marked change. In all groups and at 
all times, there were no significant differences compared 
to the N group. OPG mRNA expression on day 7 tended 
Fig. 2. Relative quantification of mRNA expression in bone. mRNA expressions of tumor necrosis factor (TNF)-alpha, receptor activator 
of nuclear factor kappa-B ligand (RANKL) and osteoprotegelin (OPG) do not change with etanercept (ETN) administration. Treatment 
with ETN tends to reduce the RANKL/OPG ratio. DKK-1 mRNA expression in the E group is lower than the P group. Wnt-1 mRNA ex-
pression is increased with ETN administration. N, non-immunized group; d, days after immunization. Values are the mean ± SD (n = 7). 
*P < 0.05 versus the N group.  †P < 0.05 versus the P group.
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to be higher in the E group than in the P group (P = 0.053), 
and significantly decreased in all groups and at all times 
compared with the N group, independent of ETN ad-
ministration. TNF-alpha, RANKL and OPG mRNA 
expressions were not significantly different between E 
and P groups at all times. Treatment with ETN tended 
to reduce the RANKL/OPG ratio on day 14 (P = 0.072), 
but the difference did not reach statistical significance 
at any time. DKK-1 mRNA expression in the E group 
decreased significantly on days 7 and 14 (P = 0.009, 0.033, 
respectively) compared to the P group, and tended to be 
lower than the P group on day 21 (P = 0.085). With the 
exception of day 7 in the E group, expression of Wnt-1 
mRNA significantly decreased in all groups and at all 
times compared with the N group, independent of ETN 
administration. However, ETN administration signifi-
cantly increased Wnt-1 mRNA expression on days 7 and 
21 (P = 0.014, 0.047, respectively) compared with the 
placebo administration.
 
Experiment B: Histological findings
Bone histomorphometric analysis of the posteromedial 
condyle of the femur in the mid-sagittal plane was per-
formed. The pannus volume and pannus surface were 
not significantly different between the groups (P = 0.478, 
0.718, respectively) (Table 2). The average number of os-
teoclasts on the pannus surface did not change with ETN 
administration (P = 0.398). Osteoid volume, osteoid sur-
face and labeling surface on the surface of the pannus 
increased significantly with ETN administration (P < 
0.001). The number of HPF, which met the above con-
ditions, varied across sections (2–5 fields per section). 
Totals of 55 and 53 HPF were examined in the P group 
and E group, respectively. The number of plasma cells, 
macrophages and blood vessels per HPF were not sig-
nificantly different between the groups (P = 0.355, 0.355, 
0.063, respectively) (Table 3). Histologic sections of the 
knee joint stained with Villanueva bone stain are shown 
in Fig. 3. The pannus infiltrated the posteromedial femo-
ral condyle (Fig. 3a). Although pannus formation and 
bone destruction were not different between the E group 
(Fig. 3b) and P group (Fig. 3d), more osteoid production 
(Fgs. 3b and d: black arrowheads) and bone calcifica-
tion (Figs. 3c and e: white arrowheads) were seen on the 





Genovese et al. reported that 10% (20 of 201) patients 
treated with ETN had negative change in the total 
Sharp score from the baseline on 5-year radiographs.22 
Klareskog el al. also reported similar results of radio-
graphic changes in RA patients treated with ENT and 
methotrexate combination therapy.15 It is clear that de-
velopment of several effective treatment options such as 
ETN has induced repair of bone erosions in RA, but the 
mechanism of “bone repair” is still unknown. To clarify 
this uncertain mechanism, we attempted to investigate 
“bone repair” using molecular biological and histologi-
cal methods with CIA. 
 Trentham et al. reported that sensitization to type II 
collagen caused arthritis similar to RA.20 CIA has been 
used as an RA model for studies on the pathology and 
treatment of RA. In the present study, we chose knee 
joints because i) the incidence of knee arthritis was high; 
ii) arthritis of the knee tended to be severe and iii) our 
previous study investigated knee joints of CIA histologi-
cally and with molecular biology.21, 23 
 ETN is a protein that intercepts or inhibits the 
work of TNF-alpha, but does not inhibit production.3 
Therefore, it is acceptable that expression of TNF-alpha 
Table 2. Bone histomorphometry of the posteromedial femoral condyle in the mid-sagittal plane 
 PV/TV  PS/TV  Oc.N/PS  OV/PV  OS/PS LS/PS 
Group (%)  (µm/µm2)  (/mm)   (%)   (%)   (%)
E 34.3 ± 10.9 0.0014 ± 0.0005  3.13 ± 8.09  1.88 ± 1.48*  27.6 ± 12.9* 41.6 ± 14.1*
P 30.8 ± 12.8 0.0015 ± 0.0006 3.31 ± 6.77  0.21 ± 0.19  8.3 ± 5.7 11.7 ± 6.9
Values are the mean ± SD (n = 10).
LS, labeling surface; Oc.N, osteoclast number; OS, osteoid surface; OV, osteoid volume; PS, pannus surface; PV, pannus volume; TV, tis-
sue volume.
PV/unit area (TV), PS/TV and Oc.N/PS are not significantly different between the groups. OV/PV, OS/PS and LS/PS increase signifi-
cantly with etanercept administration. 
*P < 0.05 versus the P group.
Table 3. The number of plasma cells, macrophages and 
blood vessels per high power field (HPF) in the infiltrat-
ing pannus 
Group Plasma  Macro- Blood  
 cells/HPF phages/HPF vessels/HPF 
E 0.40 ± 0.33 0.26 ± 0.30 1.86 ± 0.95
P 0.56 ± 0.52 0.40 ± 0.43 2.33 ± 0.77
Values are the mean ± SD (n = 10).
There are no significant differences between the groups. 
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mRNA was not inhibited by ETN administration. Ex-
pression of RANKL and OPG were not different with 
or without ETN administration. However, treatment 
with ETN showed a tendency to reduce the RANKL/
OPG ratio. Catrina et al. reported that anti-TNF therapy 
did not suppress synovial RANKL expression, but pro-
moted OPG expression in RA patients. It was concluded 
that therapy with TNF antagonists in RA modulates the 
OPG/RANKL system, a potential mechanism that could 
explain the retardation of radiographic damage observed 
following anti-TNF therapy.24 We think our findings 
from an animal model in which anti-TNF therapy re-
duced the RANKL/OPG ratio in synovial tissue support 
their conclusion. 
 Furthermore, in our histological study, the pan-
nus volume, pannus surface and average number of 
osteoclasts on the pannus surface did not change with 
ETN administration. By the same token, the number of 
plasma cells, macrophages and synovial blood vessels 
were not significantly different among groups. This re-
sult is reasonable in the light of our analysis of mRNA 
expression that indicated ETN did not suppress RANKL 
expression. This implies ETN has limited influence on 
osteoclastogenesis. 
 In the meanwhile, from the standpoint of bone for-
mation, more osteoid and bone calcification were seen 
Fig. 3. Pannus infiltrated the posteromedial femoral condyle (a). Pannus formation and bone destruction are not different between the E 
group (b, c) and P group (d, e). More osteoid production (b, d: black arrowheads) and bone calcification (c, e: white arrowheads) are seen 
on the pannus-contacting bone surface in the E group than in the P group (Villaneuva bone stain). a: bar = 500 μm. b, d: bar = 100 μm. c, 
e: fluorescence, bar = 100 μm. C, cartilage; EL, epiphyseal line; FC, femoral condyle; PC, posterior cortex. 
on the pannus-contacting bone surface in the E group 
than in the P group. Recently, it was clarified that the 
Wnt family stimulated osteoblast formation via co-
receptor LRP5/6, and DKK, an antagonist of LRP5/6, 
suppressed osteoblast formation by blocking the Wnt 
signaling pathway.10, 25 Interestingly, Diarra et al. re-
ported bone formation in RA was hampered by TNF-
mediated expression of DKK-1.9 These facts and our re-
sults suggest that ETN suppresses DDK-1 expression via 
the blocking effect of TNF-alpha and, as a result, Wnt 
expression is promoted and osteoblastogenesis becomes 
more active independent of regulation of osteoclast ac-
tivity. Therefore, increase of bone formation is attributed 
to the fact that ETN directly promotes osteoblastogen-
esis and not as a result of suppressing osteoclastogenesis.
 Our study has a few limitations. In experiment A, 
ETN administration was started 1 day after immuniza-
tion because TNF-alpha expression began to decrease 
after peaking 7 days after immunization.23 A previous 
study reported that ETN reduced the incidence of arthri-
tis,26 so one limitation is that ETN administration was 
started before the onset of arthritis. However, in our pre-
liminary experiment, the incidence of arthritis in CIA 
rats was not significantly different between the E group 
and P group (85.7%, 89.9% respectively). In experiment 
B, ETN administration was started 3 weeks after im-
19
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munization because bone destruction was observed his-
tologically 3 weeks after immunization.21 As described 
above, if we assume that expression of TNF-alpha may 
deteriorate soon after 3 weeks’ post-initial immuniza-
tion, ETN may be no longer involved in the regulation of 
osteoclastogenesis from that point onwards. As a result, 
bone resorption during histomorfometry was not down-
regulated. ETN administration was started less than 3 
weeks after immunization, which may cause inhibition 
of pannus formation itself. This is the second limitation 
of this study.
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